vTv Therapeutics Inc Total Liabilities
vTv Therapeutics Inc total liabilities. Based on the latest financial reports, vTv Therapeutics Inc (VTVT) has total liabilities worth $8.96 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check vTv Therapeutics Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of vTv Therapeutics Inc (2013–2025)
Total liabilities of vTv Therapeutics Inc from 2013 to 2025. This chart illustrates how vTv Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore vTv Therapeutics Inc long-term investment allocation to see how much of total assets are deployed in long-term investments.
vTv Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of vTv Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Thinkific Labs Inc
TO:THNC
|
Canada | CA$19.80 Million |
|
aTyr Pharma, Inc.
NASDAQ:ATYR
|
USA | $26.88 Million |
|
Inspired Entertainment Inc
NASDAQ:INSE
|
USA | $408.50 Million |
|
51 TALK ONL. SP.ADR A 60
F:C4G0
|
Germany | €98.81 Million |
|
Guerbet S. A.
PA:GBT
|
France | €669.94 Million |
|
Chainqui Construction Development Co Ltd
TW:2509
|
Taiwan | NT$10.34 Billion |
|
Indústrias Romi S.A
SA:ROMI3
|
Brazil | R$1.35 Billion |
|
Fifth District Bancorp, Inc. Common Stock
NASDAQ:FDSB
|
USA | $403.12 Million |
Liability Composition Analysis (2013–2025)
This chart breaks down vTv Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VTVT current and non-current assets.
Liquidity & Leverage Metrics
vTv Therapeutics Inc Total Liabilities Ratios Explained
vTv Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.11 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how vTv Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for vTv Therapeutics Inc (2013–2025)
The table below shows the annual total liabilities of vTv Therapeutics Inc from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $25.46 Million | +6.25% |
| 2024-12-31 | $23.96 Million | -18.95% |
| 2023-12-31 | $29.57 Million | +7.91% |
| 2022-12-31 | $27.40 Million | +167.26% |
| 2021-12-31 | $10.25 Million | -6.77% |
| 2020-12-31 | $11.00 Million | -39.27% |
| 2019-12-31 | $18.11 Million | -80.19% |
| 2018-12-31 | $91.41 Million | -48.92% |
| 2017-12-31 | $178.96 Million | +23.05% |
| 2016-12-31 | $145.44 Million | -14.20% |
| 2015-12-31 | $169.50 Million | -66.88% |
| 2014-12-31 | $511.76 Million | +60.31% |
| 2013-12-31 | $319.24 Million | -- |
About vTv Therapeutics Inc
vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes. The company… Read more